Cancer is detected through a combination of physical exams, imaging scans, blood tests, biopsies, and genetic testing. No single test catches every type of cancer. Instead, doctors typically start with less invasive methods and move toward more specific ones as needed, narrowing down whether abnormal cells are present, where they are, and what type they are.
Physical Examination
Detection often starts with a hands-on exam. Doctors feel for lumps, swollen lymph nodes, or organs that seem larger than normal. What they’re checking isn’t just whether something is there, but what it feels like. A soft, tender lymph node usually points to infection. A hard, painless one is more characteristic of cancer. Rubbery nodes suggest lymphoma specifically. Symmetry matters too: cancerous nodes tend to appear on one side rather than both.
Certain locations raise more concern than others. A swollen node just above the collarbone is particularly significant because it often signals a problem deeper in the body. A node above the left collarbone classically points to something in the abdomen, while one on the right side suggests a process in the chest. Nodes below the collarbone are associated with breast cancer or lymphoma. For skin cancers, doctors evaluate moles using the ABCDE criteria: asymmetry, border irregularity, color variation, diameter larger than a pencil eraser, and evolving shape or size.
Imaging Scans
When a physical exam raises suspicion, imaging lets doctors look inside the body without surgery. Each type of scan serves a different purpose.
CT scans use a thin X-ray beam to build detailed cross-sectional images of organs, bones, and blood vessels. They show far more detail than a standard X-ray and are commonly used to find tumors, measure their size, and check whether cancer has spread.
MRI scans use a powerful magnet and radio waves instead of radiation. They’re especially good at producing detailed images of soft tissue, making them useful for brain tumors, spinal cord tumors, and cancers in organs like the liver or prostate.
PET scans work differently from both. Rather than showing what structures look like, a PET scan shows how cells are functioning. Cancer cells burn through energy faster than normal cells, and a PET scan picks up that increased activity. This means a PET scan can sometimes detect cancer before a tumor is large enough to appear on a CT or MRI. It’s particularly useful for determining whether cancer has spread to other parts of the body.
Ultrasound uses sound waves to create real-time images and carries no radiation risk. It’s often the first imaging tool used for lumps in the breast, thyroid, or testicles, and it helps guide needles during biopsies.
Endoscopy
For cancers inside hollow organs like the colon, stomach, lungs, or esophagus, doctors use an endoscope: a long, thin tube with a light and camera at the tip. The scope sends live images to a screen, letting the doctor examine the lining of an organ directly. The most familiar example is a colonoscopy, but the same principle applies to procedures examining the throat, airways, bladder, and other areas.
What makes endoscopy especially valuable is that it combines detection with action. The scope has channels that allow doctors to pass small instruments through it, so if they spot suspicious tissue, they can remove a sample for testing during the same procedure. They can also remove small polyps or growths on the spot before they have a chance to become cancerous.
Biopsy: The Definitive Test
Imaging and blood tests can suggest cancer, but a biopsy is what confirms it. A biopsy removes a sample of suspicious tissue so it can be examined under a microscope. There are several approaches depending on where the tissue is and how much is needed.
Fine-needle aspiration uses a thin needle and syringe to draw out fluid and cells. It’s quick, minimally invasive, and commonly used for lumps in the thyroid, breast, or lymph nodes. Core needle biopsy uses a slightly larger needle with a cutting tip to extract a small column of tissue, providing more material for analysis. Surgical biopsy involves making an incision to access deeper tissue. Surgeons may remove just a portion of the suspicious area or take out the entire growth.
Once collected, the tissue sample goes to a pathology lab. It’s either chemically treated or frozen, sliced into extremely thin sections, placed on glass slides, and stained to make cellular details visible under a microscope. A pathologist then determines whether cancer cells are present, what type they are, and how abnormal they look. Simple biopsies typically take two to three days to process. Larger cancer cases take around five days. If the lab needs additional steps like special stains or consultations with other pathologists, each step can add one to two more days.
Blood Tests and Tumor Markers
Blood tests alone rarely diagnose cancer, but they can provide important clues and are essential for monitoring treatment. Tumor markers are proteins or other substances that cancer cells (or normal cells reacting to cancer) release into the bloodstream. Elevated levels can prompt further testing or help track how well treatment is working.
Some commonly used tumor markers include:
- CA-125: Used to help diagnose ovarian cancer and monitor for recurrence
- CA 19-9: Associated with pancreatic, gallbladder, and bile duct cancers
- CEA: Tracked in colorectal cancer to check treatment effectiveness and detect recurrence
- AFP: Helps diagnose liver cancer and certain ovarian cancers
- Calcitonin: Used for medullary thyroid cancer diagnosis and monitoring
The important caveat is that tumor markers can be elevated for reasons other than cancer, including infections, inflammation, and benign conditions. That’s why they’re rarely used as standalone screening tools. They’re most valuable when combined with imaging and biopsy results, or when tracking a known cancer over time.
Genetic Testing
Genetic testing in cancer detection serves two distinct purposes, and understanding the difference matters.
Germline testing checks your inherited DNA, using a sample from normal (non-cancer) cells, typically a blood draw or cheek swab. It identifies gene mutations you were born with that increase your risk of developing cancer. The best-known examples are BRCA1 and BRCA2 mutations, which significantly raise the risk of breast and ovarian cancer. If a germline mutation is found, it has implications not just for you but for your blood relatives, who may carry the same variant.
Somatic testing analyzes the DNA of cancer cells themselves, either from a tumor tissue sample or through a liquid biopsy (a blood draw that captures fragments of tumor DNA circulating in the bloodstream). The goal here isn’t to assess inherited risk. It’s to identify mutations driving the cancer’s growth so doctors can choose targeted therapies. Some treatment centers now perform both tests simultaneously, comparing tumor DNA against normal DNA to pinpoint exactly which mutations originated in the cancer versus which were inherited.
Routine Screening by Cancer Type
Many cancers are caught through routine screening before symptoms appear. Current recommendations vary by cancer type and personal risk factors, but the major ones follow consistent guidelines.
For colorectal cancer, the U.S. Preventive Services Task Force recommends screening for adults ages 45 to 75. Options range from annual stool-based tests to a colonoscopy every 10 years for people at average risk. A stool DNA test, which looks for both blood and genetic markers shed by abnormal cells, is recommended every three years. For breast cancer, mammograms are the standard screening tool, generally starting at age 40. Lung cancer screening with a low-dose CT scan is recommended for adults ages 50 to 80 who have a significant smoking history.
These screening intervals are designed for people at average risk. If you have a family history of cancer or a known genetic mutation, your doctor will typically recommend starting earlier and screening more frequently.
How AI Is Changing Detection
Artificial intelligence is increasingly being used alongside radiologists and endoscopists to catch cancers that human eyes might miss. A 2025 meta-analysis in the Journal of the American College of Radiology pooled data from dozens of clinical trials and found measurable improvements across several cancer types. AI-assisted colonoscopy increased adenoma detection rates by 22% and polyp detection by 20%. For lung cancer, AI more than doubled the detection of actionable lung nodules. Prostate cancer detection improved by 40%, and breast cancer detection saw a 20% increase.
The technology didn’t help equally everywhere. No significant improvement was found for gastric or liver cancer detection. But for the cancers where it does work, AI functions as a second set of eyes, flagging areas on a scan or during a live procedure that warrant closer inspection. It doesn’t replace the doctor’s judgment, but it reduces the chance that something subtle gets overlooked.